一种新型量表的开发及其效用，该量表可量化6个月内1型糖尿病的血糖进展情况。
The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.
作者信息
Sosenko Jay M, Skyler Jay S, Beam Craig A, Boulware David, Mahon Jeffrey L, Krischer Jeffrey P, Greenbaum Carla J, Rafkin Lisa E, Matheson Della, Herold Kevan C, Palmer Jerry P
机构信息
Division of Endocrinology, University of Miami, Miami, FL
Division of Endocrinology, University of Miami, Miami, FL.
出版信息
Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.
OBJECTIVE
We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D.
RESEARCH DESIGN AND METHODS
The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors.
RESULTS
The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all).
CONCLUSIONS
The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.
目的
我们开发了一种量表，作为1型糖尿病（T1D）患者自身抗体阳性亲属向T1D进展的6个月血糖进展（PS6M）的潜在终点。
研究设计与方法
PS6M是根据糖尿病预防试验1型（DPT-1）数据开发的，并在TrialNet预防研究途径（PTP）中进行了测试。它是6个月血糖总和值（口服葡萄糖耐量试验30 - 120分钟的值）与非进展者预测值之间的差值。
结果
PS6M在PTP中可预测T1D（P < 0.001）。PS6M的受试者工作特征曲线下面积比基线至6个月差值的曲线下面积更大（P < 0.001）。在具有两种或更多自身抗体、30 - 0分钟C肽值<2.00 ng/mL或DPT-1风险评分>7.00的人群中，PS6M值更高（所有P均< 0.001）。
结论
PS6M是向T1D进展的短期血糖进展指标，可能是评估预防性治疗和生物标志物的有用工具。
Zotero 插件